Determining the source of symptoms in those with musculoskeletal pain is extremely important, as it sets the foundation for ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

This approval marks the first time a drug from this new class of pain management medicines has been approved ... The approval of Journavx was granted to Vertex Pharmaceuticals Incorporated. This ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...

Certain drugs and a host of nonpharmacologic therapies are key to treating patients who have nociplastic pain, a relatively ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor ...

“At Vertex, we have had a longstanding thesis around specialised AI applications solving vertical use cases. Spyne has proven ...

Spyne, an AI-powered visual merchandising platform for the automotive industry, has raised $16 million in a Series A funding ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...